MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s43018-026-01120-7

Медицинская библиотека · Nature cancer · 2026

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results.

Murthy Rashmi K, O'Brien Barbara J, Berry Donald A, Singareeka-Raghavendra Akshara, Monroe Maria Gule, Johnson Jason, White Jason, Schwartz-Gomez Jill, Topletz-Erickson Ariel, Lobbous Mina, Riley Kristen, Melisko Michelle, Morikawa Aki, Ferguson Sherise D, de Groot John F, Krop Ian E, Valero Vicente, Rimawi Mothaffar F, Wolff Antonio C, Tripathy Debu, Lin Nancy U, Stringer-Reasor Erica M

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

Treatments for leptomeningeal metastasis (LM) are limited and prognosis is poor. In this phase 2, nonrandomized, single-arm, multicenter study, we evaluated a tucatinib-trastuzumab-capecitabine regimen in patients with newly diagnosed LM and human epidermal growth factor receptor 2-positive (HER2+) breast cancer. The primary endpoint was overall survival; secondary endpoints included central nervous system progression-free survival, LM objective response, neurological symptom improvement, pharmacokinetics and safety. The trial met its prespecified interim efficacy threshold and exceeded the historical control of 4.4 months. Among 17 enrolled women, all had magnetic resonance imaging-confirmed LM, 15 (88%) were symptomatic and 8 (47%) had abnormal cerebrospinal fluid cytology. For a median follow-up of 18 months (range 9.0-26.7 months), 6 of 17 (41%) remained alive. Tucatinib reached therapeutic levels in the cerebrospinal fluid. The median overall survival was 10 months (95% confidence interval 4.1 months, not reached). The median time to central nervous system progression was 6.9 months (95% confidence interval 2.8, 13.8 months). Of 13 response-evaluable patients, 5 (38%) achieved composite LM objective response. Of 12 evaluable patients, 7 (58%) had improved neurological deficits. This prospective study suggests clinical benefit with a systemic regimen for HER2+ LM including objective responses, improved symptoms and extended survival. These data support systemic therapy as an approach in HER2+ breast cancer LM. ClinicalTrials.gov registration: NCT03501979 .

Для цитирования: Murthy Rashmi K, O'Brien Barbara J, Berry Donald A, Singareeka-Raghavendra Akshara, Monroe Maria Gule, Johnson Jason, White Jason, Schwartz-Gomez Jill, Topletz-Erickson Ariel, Lobbous Mina, Riley Kristen, Melisko Michelle, Morikawa Aki, Ferguson Sherise D, de Groot John F, Krop Ian E, Valero Vicente, Rimawi Mothaffar F, Wolff Antonio C, Tripathy Debu, Lin Nancy U, Stringer-Reasor Erica M. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results.. Nature cancer. 2026. DOI: 10.1038/s43018-026-01120-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.